Background: Early diagnosis is the key to improving outcomes for patients with melanoma, and this requires a standardized histological assessment approach. The objective of this survey was to understand the challenges faced by clinicians when assessing melanoma cases, and to provide a perspective for future studies. Methods: Between April 2022 and February 2023, national and international dermatologists, pathologists, general practitioners, and laboratory managers were invited to participate in a six-question online survey. The data from the survey were assessed using descriptive statistics and qualitative responses. Results: A total of 54 responses were received, with a 51.4% (n= 28) full completion rate. Of the respondents, 96.4% reported ambiguity in their monthly melanoma diagnosis, and 82.1% routinely requested immunohistochemistry (IHC) testing to confirm diagnosis. SOX10 was the most frequently requested marker, and most respondents preferred multiple markers over a single marker. Diagnostic and prognostic tests, as well as therapeutic options and patient management, were all identified as important areas for future research. Conclusions: The respondents indicated that the use of multiple IHC markers is essential to facilitate diagnostic accuracy in melanoma assessment. Survey responses indicate there is an urgent need to develop new biomarkers for clinical decision making at multiple critical intervention points.
背景：早期诊断是改善黑色素瘤患者预后的关键，这需要标准化的组织学评估方法。本次调查旨在了解临床医生在评估黑色素瘤病例时面临的挑战，并为未来研究提供方向。方法：2022年4月至2023年2月期间，我们邀请国内外皮肤科医生、病理学家、全科医生及实验室管理人员参与一项包含六个问题的在线调查。采用描述性统计与定性分析相结合的方法对调查数据进行了评估。结果：共回收54份问卷，完整填写率为51.4%（n=28）。96.4%的受访者表示每月都会遇到诊断不明确的黑色素瘤病例，82.1%的受访者会常规要求进行免疫组化检测以明确诊断。SOX10是最常被要求检测的标志物，多数受访者倾向于采用多标志物联合检测而非单一标志物。诊断与预后检测、治疗方案选择及患者管理均被确定为未来研究的重要方向。结论：受访者指出使用多种免疫组化标志物对提高黑色素瘤诊断准确性至关重要。调查结果表明，亟需开发新的生物标志物以支持临床在多个关键干预节点作出决策。
Insights into Melanoma Clinical Practice: A Perspective for Future Research
肿瘤(癌症)患者之家